Skip to main content

Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Web Exclusives - Breast Cancer, FDA Approvals, Select Drug Profiles

On March 13, 2017, ribociclib (Kisqali; Novartis) became the third CDK4/CDK6 inhibitor to be approved by the FDA. The FDA approved ribociclib, in combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Ribociclib received a breakthrough therapy designation and was approved under the FDA’s priority review process.

This approval was based on the phase 3 MONALEESA-2 clinical trial that included 668 treatment-naïve postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The patients were randomized to ribociclib plus letrozole or placebo plus letrozole.

Ribociclib plus letrozole reduced mortality risk by 44%. The median progression-free survival (PFS) was not reached in the ribociclib plus letrozole combination (95% CI, 19.3-not reached) and was 14.7 months with letrozole and placebo (P <.0001). The ORR was 52.7% versus 37.1%, respectively. In another analysis with an 11-month follow-up, the PFS was 25.3 months with the addition of ribociclib and 16 months with letrozole alone.

“These results affirm that combination therapy with a CDK4/6 inhibitor like ribociclib and an aromatase inhibitor should be a new standard of care for initial treatment of HR+ advanced breast cancer,” said Gabriel N. Hortobagyi, MD, Professor of Medicine, Department of Breast Medical Oncology, M.D. Anderson Cancer Center, Houston, and principal investigator of MONALEESA-2.

The most common all-grade adverse reactions with ribociclib plus letrozole included neutropenia (75%), leukopenia (33%), headache (22%), back pain (20%), nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), alopecia (33%), and fatigue (37%). Dose reductions because of adverse reactions were 45% with the active combination versus 3% with letrozole and placebo. Permanent discontinuation of therapy was reported in 7% of patients versus 2%, respectively.

Related Items
Radiation May Be Safely Omitted in Favorable-Risk Breast Cancer Patients Aged 50 to 69 Years
Phoebe Starr
Web Exclusives published on March 1, 2024 in Breast Cancer
Directory of FDA Approvals, August Through December 2023
December 2023 Vol 16, Payers' Guide to FDA Updates published on January 26, 2024 in FDA Approvals
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 16, 2024 in FDA Approvals
Ogsiveo First Treatment FDA Approved for Desmoid Tumors
Web Exclusives published on January 2, 2024 in FDA Approvals
Last modified: August 30, 2021